Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Alumis Inc. Common StockNASDAQ: ALMS

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $14.27M fell 23.4% year over year, behind the -7.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 15.7% from the prior quarter. Over 3 fiscal years it compounded at +94.0% a year.

Context

  • Stock-based compensation amounted to 181.0% of revenue in FY2025.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -23.4% toward the trailing-twelve-month pace of -7.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$14.27M+15.7% QoQ
Last fiscal yearDec 2025
$43.52M+123.7% YoY
LTMJun 2026
$36.4M-7.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.4%——
1 year+123.7%——
3-year CAGR+94.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
43.52M USD
Year-over-year change
+123.7%
3-year CAGR
+94.0%

Stock-Based Compensation vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.4% is the 5th highest of 8, against a peer median of -2.1%.
  • Stock-based compensation amounts to 492.0% of revenue for ALMS, versus a peer median of 144.0%.
ALMS Competitors
Stock-Based Compensation for ALMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$41.12M USD+24.3%+9.7%17.7%
ALMSAlumis Inc. Common StockLTM Jun 2026$36.4M USD-7.4%+94.0%492.0%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$13.96M USD+64.9%+21.7%23652.5%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.84M USD+21.4%+0.9%4.3%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M USD-2.1%-6.3%144.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$6.36M USD-16.6%+1.2%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.88M USD-66.7%-9.8%—
IFRXInflaRx N.V.LTM Mar 2026€2.48M EUR-152.9%—8455.2%
TLSATiziana Life Sciences LtdFY2025$0 USD———
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ALMS) —-2.1%+1.0%144.0%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Depreciation & Amortization250K1.28M3.15M3.5M
Deferred Income Tax000(8.56M)
Stock-Based Compensation5.96M8.63M19.46M43.52M
Change in Working Capital(1.92M)12.06M14.76M26.32M
Accounts Receivables0000
Inventory0000
Accounts Payables1.29M(642K)8.51M(6.04M)
Other Working Capital(3.21M)12.7M6.25M32.35M
Other Non-Cash Items(86K)3.05M1.79M(190.98M)
Operating Cash Flow(107.72M)(129.98M)(255.08M)(369.52M)
Capital Expenditures(2.41M)(4.5M)(1.73M)(653K)
Acquisitions (Net)0000
Purchases of Investments(209.08M)(11.28M)(240.06M)(209.17M)
Sales of Investments142.73M76.25M128M447.96M
Other Investing Activities00049.74M
Investing Cash Flow(68.75M)60.47M(113.79M)287.88M
Debt Repayment0000
Common Stock Issued00193.32M2.08M
Common Stock Repurchased000(17K)
Dividends Paid0000
Other Financing Activities1.73M(96K)40.59M0
Financing Cash Flow101.63M89.68M492.37M2.07M
Effect of Forex Changes0000
Net Change in Cash(74.85M)20.18M123.5M(79.58M)
Free Cash Flow(110.13M)(134.47M)(256.81M)(370.18M)

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.